Should I open or buy an Any Lab Test Now franchise in 2027?

The Real Numbers

An Any Lab Test Now center leases 1,000-1,800 sq ft for a retail lab-testing storefront — consumers walk in, order tests directly (self-pay), get a sample drawn, and receive results (lab work done via partner labs). The self-pay model avoids insurance-billing complexity, and B2B employer testing (drug/wellness screens) adds revenue.

Revenue reality: mature centers gross $400K-$1M across consumer self-pay tests (wellness panels, DNA, STD, allergy, etc.) and B2B employer testing (drug/alcohol/wellness screens). With phlebotomy/staff labor, lab-partner costs, rent, and royalty, owners clear $80K-$220K. The self-pay model avoids insurance-billing complexity (simpler than urgent care), the lower capital improves return-on-investment, and B2B employer testing adds recurring revenue. The challenges are building consumer and employer demand and managing the lab-partnership model.

Who Wins With This Business

• Capital required: $130K-$230K, with $60,000-$110,000 liquid — lower than urgent care.
• Time commitment: business-hours operation.
• Skills: retail/healthcare operations, consumer marketing, and B2B (employer) sales.
• Geographic fit: population-dense markets with health-conscious consumers and employers.
• Lifestyle fit: hands-on, business-hours.

The winners are operators who build both consumer and B2B employer testing demand.

Who Loses With This Business

• Operators who can't build consumer/employer demand.
• Those weak at B2B (employer) sales.
• Markets with low health-conscious or employer demand.
• Weak-location centers.
• Those who underestimate marketing for awareness (consumer education needed).

2027 Market Conditions

• Demand: consumer-driven, direct-access health testing is growing — people want convenient, transparent, self-pay testing without doctor/insurance hassle.
• Self-pay simplicity: no insurance billing — simpler than urgent care/medical models.
• B2B testing: employer drug/wellness screens add recurring revenue.
• Lower capital: accessible healthcare-franchise entry.
• Competition: LabCorp/Quest retail, telehealth labs, and online test kits.

The 90-Day Decision Tree

1. Day 1-15: Read the 2026 FDD and confirm the self-pay, direct-access model.
2. Day 16-30: Interview 8+ owners; ask about consumer vs B2B mix, employer contracts, and net profit.
3. Day 31-45: Validate a consumer-health and employer-dense market.
4. Day 46-65: Secure a site and train staff (phlebotomy).
5. Day 66-85: Build out and open the testing center.
6. Drive consumer self-pay testing and B2B employer screens.
7. Ongoing: build recurring employer-testing contracts.

Alternative Plays

• American Family Care / AFC — urgent care (higher capital, insurance-based).
• The DRIPBaR / IV-wellness — adjacent consumer-health franchises.
• Drug-testing/occupational-health businesses — adjacent B2B models.
• Restore Hyper Wellness / iCRYO — wellness franchises (in the Pulse library).
• Independent lab-testing business — full control, but no brand/lab partnerships.
• Other consumer-health franchises — adjacent models.

The 2027 Franchisee Profile: Who Thrives (and Who Struggles)

Any Lab Test Now is not a passive investment. The franchise works best for owner-operators with a healthcare, sales, or business-to-business background who are comfortable being the face of their center in the local community. The model is lean — you’ll likely run the lab draw station yourself for the first 6–12 months, handling everything from patient intake to specimen processing to employer account management.

Ideal candidates typically have:

• $80,000–$150,000 in liquid capital (beyond the franchise fee and initial investment)
• Experience in outside sales or employer services — the B2B drug-testing and wellness panel side often drives 40–60% of mature center revenue
• A willingness to work a 45–55 hour week during the first two years, especially on building relationships with local HR directors, construction firms, and school districts
• Comfort with a cash-only, no-insurance model — you’ll explain the value proposition dozens of times a week to customers used to copays

Who typically struggles:

• Absentee investors — the centers require daily hands-on management; a hired manager rarely replicates an owner’s sales hustle
• First-time business owners who dislike cold outreach — employer drug screening and wellness contracts require proactive calling, not just walk-in traffic
• Franchisees in markets with heavy competition from Quest/LabCorp patient service centers — those locations already offer direct-access testing in many states, often at lower cash prices

A 2023 survey of franchisees (from the brand’s FDD Item 19) showed that the top-quartile centers earned more than $150,000 in owner’s compensation, while the bottom quartile earned under $60,000 — a spread that reflects the sales-driven nature of the business. By 2027, with more consumer awareness of direct-access testing post-pandemic, the top performers may widen that gap further.

Site Selection and Territory Economics: Where the Model Works Best

Any Lab Test Now’s real estate strategy is strip-center based, high-visibility, and low-rent — typically 1,200–1,800 square feet in a retail plaza with strong demographics. The brand’s corporate team handles site approval, but you’ll need to be realistic about what a “good” territory looks like in 2027.

Key site criteria that matter:

• Daily traffic count above 25,000 vehicles — walk-in consumer testing relies on impulse and convenience
• Median household income of $65,000–$100,000 — the self-pay model works best where customers have disposable income and no desire to wait for a doctor appointment
• Proximity to employers with 50+ employees — companies needing DOT drug screens, pre-employment panels, or annual wellness blood work are the backbone of recurring revenue
• At least 2–3 miles from a Quest Diagnostics or LabCorp patient service center — direct competition on cash prices can squeeze margins

Territory economics to watch:

• Protected territory radius is typically 2–3 miles (check the 2026 FDD for exact language) — you’ll need to generate enough volume within that area to hit breakeven
• Average transaction value runs $80–$120 for consumer tests (single blood panel) and $200–$400 for employer drug screens (including collection fees)
• Walk-in consumer traffic usually accounts for 30–40% of revenue; employer/B2B contracts make up the rest

In 2027, expect the best-performing sites to be in suburban growth corridors with new housing developments and expanding industrial parks. Downtown urban locations often struggle because employers there already have on-site clinic options. Avoid territories where the local health department or a hospital system offers free or low-cost lab days — that directly undercuts your cash-pay model.

The 2027 Competitive Landscape: New Threats and Opportunities

The direct-access lab testing space has changed significantly since Any Lab Test Now’s 2007 founding. By 2027, you’ll face three distinct competitive forces that weren’t as strong a decade ago:

1. National lab chains with direct-to-consumer pricing. Quest Diagnostics now offers QuestDirect — over 70 lab tests available for purchase online, with results delivered digitally. LabCorp’s OnDemand offers similar. These services undercut Any Lab Test Now on price (a basic thyroid panel might be $29–$39 online vs. $49–$69 at a franchise). However, they lack the physical draw station experience and same-day walk-in convenience that drives your value.

2. At-home testing kits. Companies like Everlywell, LetsGetChecked, and Thorne sell mail-in kits for everything from food sensitivity to testosterone. These are cheaper and more private, but they don’t offer same-day results or employer-required chain-of-custody drug testing — your core B2B differentiator.

3. Urgent care centers adding lab-only services. Many urgent cares now offer “lab-only” visits with no exam fee, directly competing on consumer blood work. Your advantage remains lower overhead (no exam rooms, no physician staffing) and faster turnaround for walk-in lab orders.

Opportunities to lean into by 2027:

• Employer consortiums — partner with local chambers of commerce to offer group-rate drug testing and wellness panels to small businesses that can’t afford on-site clinics
• Direct-to-consumer marketing for niche tests — food sensitivity, heavy metal, hormone panels (these have higher margins and less price sensitivity)
• Telehealth integration — some franchisees now offer a $10–$15 virtual consult with a partner NP to generate a lab order on-site, capturing customers who don’t have a doctor’s order

The franchise’s survival depends on owning the employer drug-testing relationship — that’s the sticky, recurring revenue stream that at-home kits and national chains can’t easily replicate. If you can lock in 10–20 employer contracts within your first year, the consumer walk-in business becomes bonus revenue rather than your lifeline.

FAQ

What exactly does an Any Lab Test Now franchise do? It operates walk-in centers where consumers order their own lab tests—like blood work, wellness panels, or DNA tests—without needing a doctor’s visit or insurance. The business model is self-pay, so you collect payment upfront and send samples to partner labs for processing.

How much money do I need to start one? The total investment range in the 2026 FDD is roughly $130,000 to $230,000, including a $35,000 franchise fee. That’s significantly lower than opening an urgent care or primary care clinic, which often requires $500,000 or more.

What are the ongoing fees and royalties? You’ll pay a royalty of about 7% of gross sales plus a marketing fee. These are typical for healthcare-related franchises and help cover brand support, national advertising, and lab partnerships.

How much can I expect to earn? Mature centers typically gross between $400,000 and $1,000,000 annually, with owner net income in the $80,000 to $220,000 range. Actual results vary widely based on location, local demand, and how well you build employer B2B testing contracts.

What’s the biggest challenge in running this franchise? Building consistent consumer and employer demand is the hardest part. You’re not just running a retail lab—you need to market to local businesses for drug screening and wellness testing, and educate walk-in customers about the convenience of direct-access testing.

Do I need a medical background to operate one? No, you don’t need to be a doctor or nurse. The model relies on a partnership with a CLIA-certified reference lab that handles the actual testing. Your role is managing the front-end customer experience, sales, and operations.

Bottom Line

Open an Any Lab Test Now if you want a lower-capital ($130K-$230K) healthcare-services franchise riding the consumer-driven, direct-access lab-testing trend, with self-pay simplicity (no insurance billing), B2B employer-testing revenue, and you'll build consumer and employer demand. Its lower capital, self-pay simplicity, and B2B revenue are genuine strengths versus higher-capital medical franchises. Skip it if you can't build consumer/employer demand, are weak at B2B sales, or are in a low-demand market. For operators wanting accessible healthcare-franchise entry, Any Lab Test Now offers a capital-efficient, dual-channel (consumer + B2B) testing franchise.

Related on PULSE

• [How Many Sales Reps Do I Need to Hire for My Clinical Lab Services Company?](/knowledge/q15950)
• [How Do I Budget an Optometry Office With an On-Site Lab?](/knowledge/q13820)
• [How are 2027 buying committees using generative AI to compare vendor pricing before any contact?](/knowledge/q16659)
• [What Questions Should I Ask Before Signing Any Commercial Lease?](/knowledge/q13708)
• [How do 2027 B2B sales teams handle deal progression when buyers demand AI-generated custom ROI models before any vendor presentation?](/knowledge/q13575)
• [How do you preserve sales-team trust through any operational crisis in 2027?](/knowledge/q12420)

Sources

• Any Lab Test Now Franchise Disclosure Document (2026 filing) — Items 5, 6, 7, 19, 20
• Any Lab Test Now official franchise site — investment range and direct-access model
• Entrepreneur Franchise listings — Any Lab Test Now
• Franchise Business Review — healthcare-franchise satisfaction data
• IBISWorld — Diagnostic & Medical Laboratory Services in the US, 2026 industry report
• Statista — US consumer-health-testing and lab market, 2025-2026
• International Franchise Association (IFA) — 2027 Franchise Economic Outlook
• Consumer-directed health-testing and employer-testing market data 2026
• Workplace drug-testing market reports 2026
• US Census — population-density and employer demographic data, 2025-2026